Menopause Practice Questions

Q: Earliest menopausal symptom is :

Hot flushes. ***Hot flushes*** - **Hot flushes** are the **earliest and most common vasomotor symptom** experienced by women during perimenopause due to fluctuating estrogen levels. - They are often the first **symptomatic complaint** that brings women to clinical attention and can begin several years before the final menstrual period. - While menstrual irregularities occur concurrently, hot flushes are considered the hallmark **early symptom** of menopausal transition. *Vaginal discharge* - **Vaginal discharge** can occur due to various reasons, including infections or hormonal changes, but it is not typically the earliest or a universal symptom of menopause. - While vaginal dryness and atrophy are common menopausal symptoms, increased discharge is not characteristic of early menopause. *Osteoporosis* - **Osteoporosis** is a long-term consequence of estrogen deficiency that develops **years after menopause**, leading to decreased bone density. - It is not an early symptom but rather a chronic condition that manifests significantly later in the postmenopausal period. *Spotting* - **Spotting** (intermenstrual bleeding) can be a sign of perimenopause as menstrual cycles become irregular. - While **menstrual irregularity** is an early feature of perimenopause, hot flushes are more consistently recognized as the **earliest symptomatic presentation** that characterizes the menopausal transition.

Q: Basanti devi, a 45-year-old woman, presents with hot flushes after cessation of menstruation. Hot flushes can be relieved by administration of the following agents:

Ethinyl estradiol. ***Ethinyl estradiol*** - **Ethinyl estradiol** is a synthetic estrogen that effectively replaces the declining estrogen levels in menopause, directly alleviating **vasomotor symptoms** like hot flashes [1, 2]. - Estrogen replacement therapy is a primary treatment for moderate to severe **menopausal symptoms** [2]. *Fluoxymesterone* - **Fluoxymesterone** is an androgen (male hormone), primarily used for male hypogonadism and certain types of breast cancer, and is not indicated for relieving menopausal hot flashes. - It would not address the underlying **estrogen deficiency** responsible for hot flashes. *Testosterone* - While testosterone levels do decline in women with age, it is not the primary hormone responsible for hot flashes and is generally used for **libido issues** or low energy, not vasomotor symptoms. - Administering testosterone could lead to **virilizing side effects**, such as hirsutism or deepening of the voice. *Danazol* - **Danazol** is a synthetic androgen and an antigonadotropin used to treat conditions like endometriosis and fibrocystic breast disease. - It acts by suppressing estrogen production and would likely **worsen hot flashes** rather than relieve them.

Q: All of the following statements about HRT (hormone replacement therapy) are true except:

It increases the risk of endometrial cancer. ***It increases the risk of endometrial cancer*** - This statement is only true for **unopposed estrogen** therapy in women with an intact uterus; combined HRT (estrogen plus progesterone) significantly **reduces** this risk. - The addition of **progesterone** to estrogen HRT is protective against endometrial hyperplasia and cancer. *It increases the risk of coronary artery disease* - Studies have shown that HRT, particularly when initiated several years after menopause, can **increase the risk of cardiovascular events**, including coronary artery disease. - The **Women's Health Initiative (WHI)** study highlighted these risks, especially in older women starting HRT. *It increases bone mineral density* - Estrogen is crucial for maintaining bone density, and HRT can **slow down bone loss** and **reduce the risk of osteoporosis and fractures** in postmenopausal women. - This is a well-established benefit of HRT for bone health. *It increases the risk of breast cancer* - Combined estrogen-progestin HRT has been consistently shown to **increase the risk of breast cancer**, especially with prolonged use (more than 3-5 years). - This increased risk is a significant concern when considering HRT.

Q: All of the following are true about hot flushes EXCEPT:

Can affect the entire body, not just specific regions. ***Can affect the entire body, not just specific regions*** - While hot flashes are experienced as a **systemic sensation of heat**, they are predominantly characterized by intense warmth in the **upper body**, head, and neck, along with sweating, flushing, and palpitations. - The sensation of warmth is usually perceived to emanate from the chest or neck, spreading upwards, rather than encompassing the entire body uniformly. *Possible role of serotonin is implicated* - The **pathophysiology of hot flashes** is complex and involves neurotransmitter systems, with **serotonin** (5-HT) pathways in the brain playing a significant role in thermoregulation. - Drugs that modulate serotonin, such as **selective serotonin reuptake inhibitors (SSRIs)**, have been shown to reduce the frequency and severity of hot flashes. *Can start several years before menopause* - **Vasomotor symptoms**, including hot flashes, often begin during the **perimenopause**, which is the transitional period leading up to menopause. - This phase typically starts several years before the final menstrual period, when **hormonal fluctuations**, particularly in estrogen levels, become more pronounced. *Can persist for several years after menopause* - For many women, hot flashes can continue for an extended period into the **postmenopausal years**. - Studies indicate that the duration of hot flashes can vary widely, with some women experiencing them for **more than 10 years** after their final menstrual period.

Q: Which of the following is an indication for use of Hormone Replacement Therapy in menopausal women:-

Hot flushes. ***Hot flushes*** - Hormone Replacement Therapy (HRT) is highly effective in alleviating **vasomotor symptoms** like hot flushes and night sweats, which can severely impact quality of life in menopausal women. - The primary goal of using HRT is to manage these **menopausal symptoms** when they are bothersome. *Post menopausal bleeding* - **Postmenopausal bleeding** is a contraindication, not an indication, for new HRT initiation as it requires investigation to rule out endometrial pathology, including cancer. - If a woman on HRT experiences bleeding, it warrants immediate investigation to determine its cause and may necessitate stopping or changing the HRT regimen. *Cardiovascular protection* - While earlier beliefs suggested HRT offered cardiovascular protection, current evidence, particularly from the **Women's Health Initiative (WHI) study**, showed that HRT does not provide primary or secondary cardiovascular protection. - In fact, HRT may increase the risk of **cardiovascular events** like stroke and venous thromboembolism, especially when initiated many years after menopause. *Pyelonephritis* - **Pyelonephritis** is an infection of the kidney, typically caused by bacteria, and is not directly related to menopausal symptoms or hormonal status. - Treatment for pyelonephritis involves **antibiotics** and supportive care, not HRT.

Q: What is the endometrial thickness threshold on ultrasound that warrants further investigation in postmenopausal bleeding?

>4 mm. ***>4 mm*** - An endometrial thickness of **greater than 4 mm** in a postmenopausal woman with bleeding is the standard threshold that warrants further investigation for potential **endometrial hyperplasia** or **endometrial cancer**. - This cutoff is recommended by major international guidelines (ACOG, RCOG) and has approximately **90-96% sensitivity** for detecting endometrial cancer. - Findings exceeding this threshold typically prompt **endometrial biopsy** or **hysteroscopy** to rule out malignancy. *<3 mm* - An endometrial thickness of **less than 3 mm** in a postmenopausal woman with bleeding is generally considered **reassuring**, with a very low risk ( 4 mm**, not a range above that cutoff. *>20 mm* - An endometrial thickness **>20 mm** is highly concerning and indicates significant pathology such as **advanced hyperplasia** or **carcinoma**. - However, the initial **threshold for investigation** is **>4 mm**, making this an unnecessarily high cutoff that would miss many cases requiring evaluation.

Q: A 45-year-old woman with irregular menses and hot flashes has a serum FSH level of 40 IU/L. What is the most likely diagnosis?

Perimenopause. ***Perimenopause*** - **Irregular menses**, **hot flashes**, and an **elevated FSH level (40 IU/L)** are classic symptoms and laboratory findings indicative of **perimenopause**. - During perimenopause, ovarian function declines, leading to decreased estrogen production and a compensatory rise in **FSH**. *Pregnancy* - Pregnancy would typically result in **amenorrhea** and specific hormonal changes such as elevated **hCG**, not an elevated FSH. - While irregular menses might precede pregnancy in some cases, the described symptoms and high FSH are not consistent with pregnancy itself. *Hypothyroidism* - Hypothyroidism can cause menstrual irregularities and fatigue, but **hot flashes** are not a typical symptom. - It would be associated with elevated **TSH** and low **thyroid hormones**, not primarily elevated FSH. *Pituitary adenoma* - A pituitary adenoma could cause menstrual irregularities and headaches or visual disturbances, depending on its size and hormone secretion (e.g., **prolactinoma**). - However, an isolated elevated FSH without other pituitary hormone abnormalities or masses on imaging is not characteristic of a pituitary adenoma.

Q: What is the first-line pharmacological treatment for managing menopausal symptoms in women without a uterus?

Estrogen-only therapy. ***Estrogen-only therapy*** - In women without a uterus (**hysterectomy**), **estrogen-only therapy** is the first-line treatment for menopausal symptoms because there is no risk of **endometrial hyperplasia** or **endometrial cancer**. - **Estrogen** effectively treats common symptoms like **hot flashes** and **vaginal dryness**. *Combined estrogen-progestin therapy* - This therapy is indicated for women with an intact uterus to protect the **endometrium** from **estrogen-induced hyperplasia** and **cancer**. - Prescribing **progestin** to a woman without a uterus offers no additional benefit and adds potential side effects. *Selective estrogen receptor modulators* - **SERMs** (e.g., **raloxifene**, **tamoxifen**) have mixed agonist/antagonist effects on **estrogen** receptors in different tissues. - While they can be used for specific conditions like **osteoporosis** or **breast cancer prevention**, they are not typically considered first-line for overall menopausal symptom management due to their varied effects and potential side effects compared to **estrogen** therapy for general menopausal symptoms. *Non-hormonal therapies* - These include **SSRIs**, **SNRIs**, **gabapentin**, and **clonidine**, which are considered for women with contraindications to **hormone therapy** or those who prefer non-hormonal options. - While effective for some symptoms, they are generally not as potent as **estrogen** for **vasomotor symptoms** and are typically considered second-line or alternative treatments.

Q: What is the most common symptom treated with hormone therapy (HT) in menopausal women?

Hot flashes. ***Hot flashes*** - **Vasomotor symptoms**, including hot flashes and night sweats, are the most frequent and bothersome symptoms experienced by menopausal women, leading them to seek medical attention and hormone therapy. - HT is highly effective in reducing the frequency and severity of hot flashes by stabilizing **thermoregulation** in the hypothalamus. *Breast cancer* - **Breast cancer** is a potential risk associated with hormone therapy, particularly with combined estrogen-progestin therapy, not a symptom treated by HT. - Women with a history of breast cancer or those at high risk are generally advised against HT due to this increased risk. *Endometriosis* - While **estrogen-dependent diseases** like endometriosis can be aggravated by HRT, endometriosis itself is a condition that typically improves after menopause. - HT is not used to treat endometriosis; in certain cases, it might be used to manage menopausal symptoms in women with a history of endometriosis after specific surgical interventions. *Uterine bleeding* - **Uterine bleeding** can be a side effect of hormone therapy, especially when progestin is not adequately balanced with estrogen in women with a uterus. - Abnormal uterine bleeding is a symptom that requires investigation to rule out other causes, and it is not a primary symptom treated by HT.

Q: How is MENOPAUSE diagnosed?

FSH levels >40 IU/L. ***FSH levels >40 IU/L*** - **Menopause is primarily a clinical diagnosis** based on 12 consecutive months of amenorrhea in women over 45 years with appropriate symptoms. - When laboratory confirmation is needed (e.g., women 40 IU/L** is the most reliable hormonal marker. - This elevation reflects **lack of ovarian follicular activity** and decreased estrogen production, leading to reduced negative feedback on the pituitary. - **Note:** FSH can fluctuate during perimenopause, so a single measurement may not be definitive. *Estradiol levels <20 pg/ml* - While **low estradiol levels** are characteristic of menopause due to ovarian failure, they are not the primary diagnostic marker. - Estradiol levels **fluctuate significantly** during the perimenopausal transition and are less reliable than FSH. - Not routinely used for diagnosis. *Progesterone levels 20 IU/L* - **LH levels** do increase during menopause due to loss of negative feedback from ovarian hormones. - However, **FSH elevation is more consistent and of higher magnitude**, making it the preferred hormonal marker when laboratory testing is indicated. - LH cutoff of >20 IU/L is lower than typical diagnostic thresholds.

Question 1

Earliest menopausal symptom is :

Accepted Answer

Hot flushes

Answer

Vaginal discharge

Answer

Osteoporosis

Answer

Spotting

Question 2

Basanti devi, a 45-year-old woman, presents with hot flushes after cessation of menstruation. Hot flushes can be relieved by administration of the following agents:

Accepted Answer

Ethinyl estradiol

Answer

Fluoxymesterone

Answer

Testosterone

Answer

Danazol

Question 3

All of the following statements about HRT (hormone replacement therapy) are true except:

Accepted Answer

It increases the risk of endometrial cancer

Answer

It increases the risk of coronary artery disease

Answer

It increases bone mineral density

Answer

It increases the risk of breast cancer

Question 4

All of the following are true about hot flushes EXCEPT:

Accepted Answer

Can affect the entire body, not just specific regions

Answer

Possible role of serotonin is implicated

Answer

Can start several years before menopause

Answer

Can persist for several years after menopause

Question 5

Which of the following is an indication for use of Hormone Replacement Therapy in menopausal women:-

Accepted Answer

Hot flushes

Answer

Post menopausal bleeding

Answer

Cardiovascular protection

Answer

Pyelonephritis

Question 6

What is the endometrial thickness threshold on ultrasound that warrants further investigation in postmenopausal bleeding?

Accepted Answer

>4 mm

Answer

<3 mm

Answer

5-10 mm

Answer

>20 mm

Question 7

A 45-year-old woman with irregular menses and hot flashes has a serum FSH level of 40 IU/L. What is the most likely diagnosis?

Accepted Answer

Perimenopause

Answer

Pregnancy

Answer

Hypothyroidism

Answer

Pituitary adenoma

Question 8

What is the first-line pharmacological treatment for managing menopausal symptoms in women without a uterus?

Accepted Answer

Estrogen-only therapy

Answer

Combined estrogen-progestin therapy

Answer

Selective estrogen receptor modulators

Answer

Non-hormonal therapies

Question 9

What is the most common symptom treated with hormone therapy (HT) in menopausal women?

Accepted Answer

Hot flashes

Answer

Endometriosis

Answer

Uterine bleeding

Answer

Breast cancer

Question 10

How is MENOPAUSE diagnosed?

Accepted Answer

FSH levels >40 IU/L

Answer

Estradiol levels <20 pg/ml

Answer

Progesterone levels <40 ng/dl

Answer

LH levels > 20 IU/L

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?